Lineage Cell Therapeutics Inc (LCTX) stock is higher by 12.60% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Lineage Cell Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LCTX!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With LCTX Stock Today?
Lineage Cell Therapeutics Inc (LCTX) stock is trading at $1.43 as of 1:51 PM on Monday, Apr 1, a decline of -$0.05, or -3.38% from the previous closing price of $1.48. The stock has traded between $1.37 and $1.52 so far today. Volume today is more active than usual. So far 1,477,306 shares have traded compared to average volume of 714,436 shares.
To screen for more stocks like Lineage Cell Therapeutics Inc click here.
More About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.
Click Here to get the full Stock Report for Lineage Cell Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
